Minh Vu Nguyet, Hau Khang Tran, Takashi Matsushita, Ha Vinh Nguyen, Bao Long Hoang, Huyen My Le, Huu Doanh Le, Van Thuong Nguyen, Gandolfi Marco, Satolli Francesca, Feliciani Claudio, Tirant Michael, Vojvodic Aleksandra, Lotti Torello
National Hospital of Dermatology and Venereology, Hanoi, Vietnam.
Hanoi Medical University, Hanoi, Vietnam.
Open Access Maced J Med Sci. 2019 Jan 28;7(2):264-268. doi: 10.3889/oamjms.2019.070. eCollection 2019 Jan 30.
B-cell activating factor (BAFF) is considered to have a role in the pathogenesis of systemic sclerosis (SSc).
We conducted a longitudinal study on early SSc patients to determine the change in BAFF serum level after treatment and its association with organ involvements.
A total of 46 patients (32 diffuse, 14 limited) were recruited, among which 35 patients (24 diffuse, 11 limited) completed 12-month follow-up.
Higher pretreatment BAFF levels were observed in patients with positive anti-topoisomerase antibody (ATA) (2252.1 ± 899.7 pg/ml versus 1475.5 ± 697.6 pg/ml in ATA-negative patients; p = 0.01) and muscular involvement (2741.9 ± 1039.9 pg/ml versus 1897.2 ± 762.9 pg/ml in patients without muscular involvement; p = 0.005). Lower levels were observed in patients with interstitial lung disease (ILD) (1926.7 ± 757.9 pg/ml versus 2721.6 ± 1131.4 pg/ml in non-ILD patients; p = 0.01). After treatment, BAFF level reduced significantly in diffuse SSc patients (1652.2 ± 892.7 pg/ml versus 2147.6 ± 945.5 pg/ml before treatment; p = 0.03).
Patients with worsening outcome had the highest pretreatment BAFF level and was associated with increased BAFF level after treatment. BAFF can be used to predict and monitor patients' response to therapy.
B细胞活化因子（BAFF）被认为在系统性硬化症（SSc）的发病机制中起作用。
我们对早期SSc患者进行了一项纵向研究，以确定治疗后BAFF血清水平的变化及其与器官受累的关系。
共招募了46例患者（32例弥漫型，14例局限型），其中35例患者（24例弥漫型，11例局限型）完成了12个月的随访。
抗拓扑异构酶抗体（ATA）阳性患者的治疗前BAFF水平较高（ATA阴性患者为2252.1±899.7 pg/ml，ATA阴性患者为1475.5±697.6 pg/ml；p = 0.01），且有肌肉受累（肌肉未受累患者为2741.9±1039.9 pg/ml，1897.2±762.9 pg/ml；p = 0.005）。间质性肺疾病（ILD）患者的水平较低（非ILD患者为1926.7±757.9 pg/ml，2721.6±1131.4 pg/ml；p = 0.01）。治疗后，弥漫性SSc患者的BAFF水平显著降低（治疗前为2147.6±945.5 pg/ml，治疗后为1652.2±892.7 pg/ml；p = 0.03）。
预后较差的患者治疗前BAFF水平最高，且与治疗后BAFF水平升高有关。BAFF可用于预测和监测患者对治疗的反应。
